Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 17, 2007

Pharmacopeia Earns $1M from Schering-Plough

  • Schering-Plough selected the first compound from its collaboration with Pharmacopeia for preclinical development. This step triggers a $1-million milestone payment to Pharmacopeia.

    "This novel compound and its promising attributes were the basis for the extension of our collaboration with Schering-Plough last fall," states Les Browne, Ph.D., president and CEO of Pharmacopeia.

    Schering-Plough is solely responsible for further development and commercialization of these candidates. However, Pharmacopeia is eligible to receive additional milestone payments related to the successful advancement of these programs and will also receive royalties on sales of any therapeutic products resulting from these programs.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »